{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:17Z","timestamp":1786986857700,"version":"build-2736575974"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["patient-research.elsevier.com","cidjournal.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.clindermatol.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T22:30:12Z","timestamp":1405031412000},"page":"502-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Contraceptive use in acne"],"prefix":"10.1016","volume":"32","author":[{"given":"Charlene","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2014.05.002_bb0005","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0625.2009.00890.x","article-title":"New developments in our understanding of acne pathogenesis and treatment","volume":"18","author":"Kurokawa","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0010","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clindermatol.2004.03.004","article-title":"Acne and sebaceous gland function","volume":"22","author":"Zouboulis","year":"2004","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1677\/joe.0.1330467","article-title":"Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands","volume":"133","author":"Choudhry","year":"1992","journal-title":"J Endocrinol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0020","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/1523-1747.ep12472330","article-title":"Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor","volume":"100","author":"Liang","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0025","first-page":"524","article-title":"The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity","volume":"76","author":"Imperato-McGinley","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 23","key":"10.1016\/j.clindermatol.2014.05.002_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2133.1982.tb01031.x","article-title":"Is the metabolism of testosterone to 5 alpha-dihydrotestosterone required for androgen action in the skin?","volume":"107","author":"Randall","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1046\/j.1523-1747.2003.12244.x","article-title":"Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1)","volume":"120","author":"Thiboutot","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1034\/j.1600-0625.2003.00014.x","article-title":"Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo","volume":"12","author":"Rosignoli","year":"2003","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1523-1747.2003.12411.x","article-title":"Expression of peroxisome proliferator-activated receptor and CCAAT\/enhancer binding protein transcription factors in cultured human sebocytes","volume":"121","author":"Chen","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archderm.135.9.1041","article-title":"Androgen metabolism in sebaceous glands from subjects with and without acne","volume":"135","author":"Thiboutot","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/1523-1747.ep12616181","article-title":"Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands","volume":"99","author":"Akamatsu","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2133.1997.tb14889.x","article-title":"Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis","volume":"136","author":"Thiboutot","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.1964.03070220021004","article-title":"Effect of cyclic progestin-estrogen therapy on sebum and acne in women","volume":"190","author":"Strauss","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.sder.2008.06.002","article-title":"Hormonal therapy for acne","volume":"27","author":"George","year":"2008","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0075","first-page":"708","article-title":"Post-adolescent acne in women: more common and more clinical considerations","volume":"11","author":"Kim","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00128071-200607050-00002","article-title":"Persistent acne in women: Implications for the patient and for therapy","volume":"7","author":"Williams","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2133.1997.tb08748.x","article-title":"Post-adolescent acne: a review of clinical features","volume":"136","author":"Goulden","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1467-2494.2004.00210.x","article-title":"Post-adolescent acne","volume":"26","author":"Knaggs","year":"2004","journal-title":"Int J Cosmet Sci"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0095","first-page":"37","article-title":"Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience","volume":"5","author":"Kim","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000067823","article-title":"Update and future of hormonal therapy in acne","volume":"206","author":"Thiboutot","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0968-0896(98)00260-0","article-title":"Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative\/antiproliferative activities","volume":"7","author":"Tremblay","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2265.1985.tb01090.x","article-title":"In-vivo metabolites of spironolactone and potassium canrenoate: Determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay","volume":"23","author":"Armanini","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0115","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","author":"Farquhar","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bpobgyn.2004.05.007","article-title":"Hirsutism and acne in polycystic ovary syndrome","volume":"18","author":"Archer","year":"2004","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000211271","article-title":"Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone","volume":"7","author":"Zouboulis","year":"1994","journal-title":"Skin Pharmacol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0130","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.1986.tb02807.x","article-title":"Lack of effect of topical spironolactone on sebum excretion","volume":"114","author":"Walton","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","volume":"115","author":"Muhlemann","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","volume":"111","author":"Goodfellow","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0150","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1468-3083.2010.03926.x","article-title":"Importance of spironolactone in the treatment of acne in adult women","volume":"25","author":"Saint-Jean","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clindermatol.2009.03.006","article-title":"Hormonal therapy for acne: why not as first line therapy? facts and controversies","volume":"28","author":"Katsambas","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0160","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1530\/acta.0.0950540","article-title":"Disturbances in sexual differentiation of rat foetuses following spironolactone treatment","volume":"95","author":"Hecker","year":"1980","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0165","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/0002-9378(95)90549-9","article-title":"Spironolactone therapy during human pregnancy","volume":"172","author":"Groves","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2007.09.024","article-title":"Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone","volume":"58","author":"Krunic","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/09513590009167685","article-title":"Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro","volume":"14","author":"Rabe","year":"2000","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/13625180400017503","article-title":"Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group","volume":"9","author":"Bitzer","year":"2004","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0185","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0190","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0190-9622(97)70112-9","article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris","volume":"37","author":"Lucky","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0195","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0029-7844(97)00059-8","article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","volume":"89","author":"Redmond","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0200","series-title":"Estrostep [package insert]","year":"2009"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0205","first-page":"975","article-title":"Evolution of progestins. Focus on the novel progestin drospirenone","volume":"47","author":"Thorneycroft","year":"2002","journal-title":"J Reprod Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","article-title":"Efficacy and safety of 3mg drospirenone\/20 mcg ethinylestradiol oral contraceptive administered in 24\/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","volume":"77","author":"Koltun","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0215","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2165\/00003495-200767120-00007","article-title":"Drospirenone\/ethinylestradiol 3mg\/20microg (24\/4day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris","volume":"67","author":"Fenton","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0220","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","article-title":"Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial","volume":"112","author":"Maloney","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0225","first-page":"1","article-title":"U S. medical eligibility criteria for contraceptive use","volume":"59","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/bmj.318.7176.96","article-title":"Mortality associated with oral contraceptive use: 25year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study","volume":"318","author":"Beral","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0235","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3949\/ccjm.70.8.681","article-title":"Update on contraception: Benefits and risks of the new formulations","volume":"70","author":"Batur","year":"2003","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/0003-4819-128-6-199803150-00008","article-title":"Epidemiology of oral contraceptives and cardiovascular disease","volume":"128","author":"Chasan-Taber","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0245","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13625180701300194","article-title":"Combined hormonal contraception and venous thromboembolism","volume":"12","author":"Martinez","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0250","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/GCO.0b013e328355871d","article-title":"Thrombotic risks of oral contraceptives","volume":"24","author":"Rott","year":"2012","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/17455057.2.5.761","article-title":"Venous thrombosis and oral contraceptives: current status","volume":"2","author":"Tchaikovski","year":"2006","journal-title":"Women Health"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0260","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2006.12.018","article-title":"Range of published estimates of venous thromboembolism incidence in young women","volume":"75","author":"Heinemann","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0265","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0270","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2008.02921.x","article-title":"Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study","volume":"6","author":"Pomp","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0275","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1701-2163(16)34746-6","article-title":"SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: An update","volume":"32","author":"Reid","year":"2010","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0280","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0412.2012.01444.x","article-title":"Hormonal contraception and venous thromboembolism","volume":"91","author":"Lidegaard","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/eurpub\/12.2.81","article-title":"Third generation oral contraceptives and vascular risks","volume":"12","author":"La Vecchia","year":"2002","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0300","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/humupd\/dms021","article-title":"Family planning 2011: Better use of existing methods, new strategies and more informed choices for female contraception","volume":"18","year":"2012","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0305","first-page":"495","article-title":"Hormonal contraception-what kind, when, and for whom?","volume":"108","author":"Wiegratz","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0310","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmq022","article-title":"Hormonal contraception and risk of cancer","volume":"16","author":"Cibula","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0315","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0320","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0325","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/bmj.298.6683.1269","article-title":"The contraceptive pill and breast cancer in young women","volume":"298","author":"Drife","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0330","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","volume":"370","author":"Appleby","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0335","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(07)61667-5","article-title":"Cervical cancer prevention and hormonal contraception","volume":"370","author":"Sasieni","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0340","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1529-8019.2009.01261.x","article-title":"Should dermatologists prescribe hormonal contraceptives for acne?","volume":"22","author":"Harper","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0345","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0010-7824(02)00326-8","article-title":"Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills","volume":"66","author":"Lara-Torre","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0350","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0010-7824(02)00351-7","article-title":"Quick start: Novel oral contraceptive initiation method","volume":"66","author":"Westhoff","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0355","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0015-0282(02)04680-0","article-title":"Bleeding patterns after immediate vs. conventional oral contraceptive initiation: A randomized, controlled trial","volume":"79","author":"Westhoff","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0360","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/01.AOG.0000264550.41242.f2","article-title":"Initiation of oral contraceptives using a quick start compared with a conventional start: A randomized controlled trial","volume":"109","author":"Westhoff","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0365","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.contraception.2011.01.021","article-title":"Contraceptive failure in the United States","volume":"83","author":"Trussell","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0370","first-page":"CD003987","article-title":"Combination contraceptives: effects on weight","author":"Gallo","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0375","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1001\/jama.285.17.2232","article-title":"Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence","volume":"285","author":"Stewart","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0380","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jwh.2010.2349","article-title":"Do new guidelines and technology make the routine pelvic examination obsolete?","volume":"20","author":"Westhoff","year":"2011","journal-title":"J Womens Health"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0385","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mjd.2002.120448","article-title":"Oral contraceptive efficacy and antibiotic interaction: A myth debunked","volume":"46","author":"Archer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0390","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0010-7824(99)00009-8","article-title":"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review","volume":"59","author":"Weaver","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0395","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0190-9622(97)80322-2","article-title":"Oral contraceptive failure rates and oral antibiotics","volume":"36","author":"Helms","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0400","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archderm.1994.01690030128027","article-title":"Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives","volume":"130","author":"London","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0405","first-page":"20","article-title":"Interaction of antibiotics and oral contraceptives","volume":"16","author":"Summers","year":"2008","journal-title":"Emerg Nurse"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0410","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00431-012-1676-x","article-title":"Clinical practice: Contraception in adolescents","volume":"171","author":"Verhaeghe","year":"2012","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0415","series-title":"iPLEDGE Program Prescriber Contraception Counseling Guide","author":"U.S. Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0420","first-page":"1","article-title":"Estimated pregnancy rates for the United States, 1990-2005: An update","volume":"58","author":"Ventura","year":"2009","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0425","first-page":"1","article-title":"Youth risk behavior surveillance-United States, 2011","volume":"61","author":"Eaton","year":"2012","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0430","series-title":"Contraceptive Technology","article-title":"Contraceptive efficacy","author":"Trussell","year":"2007"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0435","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","article-title":"Effectiveness of long-acting reversible contraception","volume":"366","author":"Winner","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0440","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1001\/jama.285.18.2347","article-title":"Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial","volume":"285","author":"Audet","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.contraception.2003.10.006","article-title":"The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy","volume":"69","author":"Archer","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0450","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.contraception.2004.09.001","article-title":"Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial","volume":"71","author":"Oddsson","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0455","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2006.07.004","article-title":"Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3mg of drospirenone","volume":"74","author":"Ahrendt","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0465","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0470","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.contraception.2007.03.003","article-title":"Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol","volume":"76","author":"Jick","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0475","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.contraception.2006.05.071","article-title":"Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch","volume":"74","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0480","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2006.01.001","article-title":"Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0485","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2009.07.004","article-title":"Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism","volume":"81","author":"Jick","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0490","doi-asserted-by":"crossref","first-page":"e2990","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0495","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.contraception.2007.03.009","article-title":"Factors associated with willingness to use the contraceptive vaginal ring","volume":"76","author":"Gilliam","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0500","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.contraception.2007.07.013","article-title":"The contraceptive vaginal ring: female adolescents' knowledge, attitudes and plans for use","volume":"76","author":"Carey","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0505","first-page":"CD003552","article-title":"Skin patch and vaginal ring versus combined oral contraceptives for contraception","author":"Lopez","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0510","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/GRF.0b013e31816d713e","article-title":"Contraceptive care for adolescents","volume":"51","author":"Whitaker","year":"2008","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0515","first-page":"383","article-title":"Determinants of bone density in young women: relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females","volume":"75","author":"Lloyd","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0520","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jadohealth.2004.07.005","article-title":"Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls","volume":"35","author":"Cromer","year":"2004","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0525","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpedi.159.2.139","article-title":"Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception","volume":"159","author":"Scholes","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0530","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00006254-200202000-00024","article-title":"Noncontraceptive health benefits of intrauterine devices: a systematic review","volume":"57","author":"Hubacher","year":"2002","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0535","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0002-9378(11)90607-3","article-title":"Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices","volume":"166","author":"Sivin","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0540","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/bmj.286.6359.106","article-title":"Fertility after stopping use of intrauterine contraceptive device","volume":"286","author":"Vessey","year":"1983","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0545","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(11)70223-6","article-title":"Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: A pooled analysis of 26 epidemiological studies","volume":"12","author":"Castellsague","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0550","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0301-2115(02)00153-7","article-title":"IUD use and the risk of endometrial cancer","volume":"105","author":"Benshushan","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0555","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2008.06.014","article-title":"Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only","volume":"111","author":"Orbo","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0560","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/01.AOG.0000291575.93944.1a","article-title":"Intrauterine device and adolescents","volume":"110","author":"ACOG Committee Opinion No. 392","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0565","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/GCO.0b013e32835686d5","article-title":"Long-acting reversible contraception for adolescents","volume":"24","author":"McNicholas","year":"2012","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0570","series-title":"Contraceptive technology","author":"Hatcher","year":"2007"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0575","first-page":"CD007373","article-title":"Interventions for pain with intrauterine device insertion","author":"Allen","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0580","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2265.1982.tb01625.x","article-title":"Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD","volume":"17","author":"Nilsson","year":"1982","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0585","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0015-0282(16)59881-1","article-title":"New insights on the mode of action of intrauterine contraceptive devices in women","volume":"49","author":"Alvarez","year":"1988","journal-title":"Fertil Steril"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0590","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.contraception.2008.08.003","article-title":"Cost effectiveness of contraceptives in the United States","volume":"79","author":"Trussell","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0595","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/AOG.0b013e31821188ad","article-title":"Continuation and satisfaction of reversible contraception","volume":"117","author":"Peipert","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0600","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/j.ajog.2012.08.002","article-title":"Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial","volume":"207","author":"Mommers","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0605","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.contraception.2011.03.001","article-title":"Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project","volume":"84","author":"Mestad","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0610","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.contraception.2004.11.007","article-title":"Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel","volume":"71","author":"Funk","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.clindermatol.2014.05.002_bb0615","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":"Safety and efficacy of a single-rod etonogestrel implant (Implanon): Results from 11 international clinical trials","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X14001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X14001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T14:20:19Z","timestamp":1565619619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X14001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0738081X14001126"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2014.05.002","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contraceptive use in acne","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}